AOD-9604

Human Growth Hormone Fragment 176-191

AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

•Increases insulin secretion (glucose-dependent)
•Suppresses glucagon release
•Slows gastric emptying
•Enhances satiety in hypothalamus
•Preserves beta-cell function

GIP Receptor Pathway

•Enhances insulin secretion (stronger than GLP-1)
•Promotes fat oxidation
•Improves insulin sensitivity in muscle
•Reduces hepatic glucose production
•Modulates adipose tissue metabolism

Why Dual Agonism is Superior

AOD-9604 represents the last 16 amino acids (176-191) of the human growth hormone molecule, specifically the region responsible for fat metabolism without growth promotion. It binds to β3-adrenergic receptors on adipocytes, activating adenylyl cyclase and increasing cyclic adenosine monophosphate (cAMP) levels. This cascade activates hormone-sensitive lipase, promoting lipolysis (fat breakdown) while simultaneously inhibiting acetyl-CoA carboxylase, reducing lipogenesis (fat formation). The peptide mimics the natural fat-burning properties of HGH without affecting growth, insulin sensitivity, or IGF-1 production.

Pharmacokinetic Profile

~5 days

Half-life

8-72 hours

Tmax

80%

Bioavailability

99%

Protein binding

Proteolytic cleavage

Metabolism

Renal (primary)

Elimination

Peptide Database